1. Treating Transplant-Ineligible Patients With Multiple Myeloma

2. This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

3. Introduction

4. Determinants of Transplant Eligibility

5. Rd (Fixed vs Continued) vs MPT in ND Transplant-Ineligible MM: FIRST Trial

6. RVD vs Rd in ND Transplant-Ineligible MM: SWOG S0777 Trial

7. Ixazomib in Transplant-Ineligible Patients

8. VRd vs Rd: SWOG S0777 Data

9. Patients Unable to Tolerate Standard Triplet Regimens

10. Bortezomib vs Lenalidomide-Based Induction by Risk Status: Pooled Analysis

11. Steroids for Frail Patients

12. Goals of Therapy

13. Monitoring

14. Comorbidities in Transplant-Ineligible MM

15. Patient Case: Sally

16. Patient Case: Workup

17. Patient Case: Discussion

18. Patient Case: Discussion (cont)

19. Selecting Treatment for Relapsed MM Is Complex

20. Future Directions: Moving Novel Agents Into Front Line

21. Minimal Residual Disease

22. Role of MRD: IFM2009 Trial

23. Key Takeaways

24. Abbreviations

25. Abbreviations (cont)

26. Abbreviations (cont)